In July 2025, the U.S. House of Representatives narrowly passed a fiscal spending and tax reform bill named the "A Big Beautiful Bill" by a vote of 218 to 214. This monumental $3.3 trillion bill is a flagship legislative effort pushed by Trump during his second term, covering areas such as tax cuts, increased defense spending, stricter immigration policies, limits on green energy subsidies, and significant adjustments to federal healthcare programs.
Unlike traditional "healthcare bills," it more closely resembles a comprehensive "fiscal + political" ledger. However, its adjustments to Medicaid, Medicare, and drug policies effectively constitute the most profound structural reform to the U.S. healthcare system since the Affordable Care Act (ACA) of the Obama era.
The Trump administration claims that this move aims to reduce "waste, fraud, and abuse," restore "fiscal discipline," and provide more tax benefits to the middle class. In reality, the bill faced internal Republican disagreements over its healthcare provisions, and its passage relied on compromise votes from a handful of conservative lawmakers.
The most controversial aspect is the significant cuts to federal healthcare spending. This will not only alter healthcare access for tens of millions of low-income and elderly Americans but also profoundly impact the business models and market dynamics of the entire pharmaceutical industry.
Members of the House walk up the steps of the U.S. Capitol during a procedural vote on the One Big Beautiful Bill Act on July 3, 2025, in Washington, D.C. (Getty/Kayla Bartkowski)
The "Big Beautiful Bill" has caused such a stir in the pharmaceutical industry not only because of its unprecedented scale but also because several core provisions directly disrupt critical mechanisms related to healthcare, drug pricing, and R&D incentives. Below, we break down five key provisions and analyze their potential impacts:
One of the most contentious provisions is the systematic reduction of Medicaid, the largest healthcare program for low-income Americans, currently covering over 70 million people. The new bill is expected to cut up to $1 trillion in funding and introduce a "work requirement" mechanism—starting in 2026, adults aged 19 to 64 without disabilities must provide proof of employment, education, or volunteer work to qualify for coverage.
On the surface, this reform encourages self-reliance, but in practice, it creates barriers for gig workers, informal laborers, and caregivers. According to the Congressional Budget Office (CBO), this reform will leave approximately 11.5 million people uninsured over the next decade, rolling back coverage to pre-Obamacare levels.
For pharmaceutical companies, this means losing a large pool of potential patients, particularly for drugs treating chronic conditions, primary care, and mental health disorders, which may see declining sales.
Orphan drugs, which treat rare diseases, often enjoy policy incentives due to limited indications and high development costs. Since 2003, the U.S. has offered incentives such as extended patent protection and tax breaks. However, after the Biden administration introduced Medicare price negotiations in 2022, these high-cost drugs faced pricing pressures.
The "Big Beautiful Bill" reverses this trend, not only maintaining exemptions for single-indication orphan drugs but also extending them to multi-indication rare disease drugs. This means that even if a drug treats two or more rare diseases, Medicare cannot negotiate lower prices as long as they remain in the rare disease category.
Pharmaceutical companies strongly welcome this change, as it opens greater opportunities for rare disease drug development and commercialization, potentially saving the industry $5 billion. It may also encourage companies to expand existing platforms into multiple rare disease indications to maximize pricing returns.
To encourage sustained investment in R&D and equipment, the bill retains and extends tax deductions for new equipment and drug development, particularly benefiting early-stage biotech companies by helping them survive the cash-burning phase.
Amid tightening financing and high costs, tax breaks serve as a critical policy tool to bolster small innovative drug companies. Some analysts believe this will stimulate early-stage activity in regenerative medicine, antibody-drug conjugates (ADCs), nuclear medicine, and gene editing technologies in the U.S.
During his first term, Trump proposed the "Most Favored Nation" (MFN) pricing mechanism, which would require Medicare to pay no more than the lowest price offered globally, aiming to force drugmakers to lower U.S. prices. However, this proposal was excluded from the "Big Beautiful Bill."
This is a "policy victory" for drugmakers: it preserves the high-price status of the U.S. market while avoiding the risk of "global price linkage," where other countries reference U.S. negotiated prices to further drive down profits.
For patients, this means drug prices may not drop significantly in the short term, particularly for cancer and rare disease treatments.
Pharmacy Benefit Managers (PBMs) act as "invisible price regulators" in the U.S. drug supply chain, negotiating prices and rebates on behalf of insurers but operating with extreme opacity.
Many in the industry had hoped the bill would introduce PBM transparency rules or rebate disclosure requirements, but these were ultimately excluded. This means that even if some drug prices decrease, retail prices may not follow, leaving patients unable to directly benefit.
Although the "Big Beautiful Bill" is packaged as a "burden-reduction + incentive" policy, its impact on the pharmaceutical industry cannot be simply categorized as "positive" or "negative." From industry structure and innovation trends to capital flows and healthcare ecosystems, we can identify five key pathways of influence:
With the price negotiation exemption mechanism in place, orphan drugs (rare disease treatments) have quickly become a market focus. On one hand, companies can maintain high prices, with profit margins far exceeding those of conventional chronic disease drugs. On the other hand, the more indications a drug covers and the broader its patient population, the stronger the "price moat" created by the exemption.
U.S. biotech companies like Sarepta and PTC Therapeutics have already begun expanding into the rare disease market through indication extensions and platform technology licensing.
Additionally, orphan drugs often benefit from FDA accelerated approvals, market exclusivity, and other policy supports. Combined with tax breaks and exemption from Medicare price negotiations, they form a perfect model of "policy moat + commercial returns." Over the next 3–5 years, global capital is expected to continue flowing into this sector.
For many preclinical or Phase I-stage biotech companies, the extension of tax breaks is nothing short of a lifeline. Small and mid-sized biopharma firms facing financing difficulties and lacking profitability can use tax optimization to alleviate financial pressures from staffing, clinical trials, and platform development.
Moreover, the U.S.'s unique "licensing-acquisition exit" pathway allows early-stage companies to focus on core pipeline development before achieving commercialization through partnerships with or acquisitions by larger pharma companies.
However, this "tax break + financial relief" window is limited. If political winds shift, these incentives could change at any time. Now is the critical moment for small and mid-sized drugmakers to accelerate clinical value creation and establish valuation anchors.
Compared to rare diseases and high-value targeted therapies, drugs for hypertension, diabetes, mental health, and other chronic conditions will face greater reimbursement pressure. On one hand, the population losing Medicaid coverage is precisely the primary consumer base for these drugs. On the other hand, cost containment will prioritize budget cuts for "high-frequency, low-value" medications.
Without commercial insurance or out-of-pocket purchases, the market for these drugs may shrink—especially for generic drugmakers reliant on the U.S. Medicaid market, posing severe challenges to sales.
Simultaneously, this could indirectly increase societal risks like "outpatient burden" and "poor medication adherence."
Medicaid cuts won’t just impact patients—they’ll also hit healthcare providers. Non-profit hospitals, community health centers, and long-term care facilities heavily dependent on government payments face structural risks like closures, mergers, and layoffs.
This means pharmaceutical companies must reevaluate traditional hospital channels and distribution mechanisms. Sales teams need to identify at-risk hospitals early and plan for coverage gaps and logistics restructuring.
Furthermore, some states may offset federal cuts by raising local taxes, creating a fragmented landscape of "highly divergent state-level Medicaid policies." This will complicate operations for pharma companies operating across multiple states.
With federal healthcare cuts, commercial insurers will shoulder more payment responsibilities. This forces drugmakers to prioritize negotiations, partnerships, and co-development frameworks with private payers, such as:
This trend means pharma sales strategies will shift from "relying on Medicare access" to "leveraging commercial negotiations + health economics data," requiring more specialized payer relations teams.
While the "Big Beautiful Bill" has passed politically, it has sparked widespread skepticism and concern among medical communities, patient advocacy groups, think tanks, and mainstream media. This backlash stems not only from the bill's impact on healthcare, taxation, and drug pricing but also from the underlying ideological conflict—whether to guarantee basic healthcare rights for all or reduce government intervention in favor of market-driven solutions.
We outline three major categories of opposition and analyze their underlying logic and political dynamics.
The American Medical Association (AMA) issued a stern statement on the day the bill passed, declaring it would "leave Medicaid-dependent patients struggling to access care."
"Today is an avoidable tragedy for patients and the healthcare system."
—AMA President Bobby Mukkamala
Key concerns include:
Emergency physician Dr. Durrani warned that if implemented as planned, Texas alone could see 20% of its population lose coverage, leading to 55,000 additional preventable deaths annually.
"If you lose insurance, you won’t manage your diabetes—you’ll wait until kidney failure brings you to the ER. We’ll see waves of 'out-of-control patients.'"
—DW Interview, 2025
The organization "Patients for Affordable Drugs Now" condemned the bill as:
"A taxpayer giveaway to Big Pharma."
They particularly oppose the expansion of orphan drug exemptions, arguing it will lock in high prices for certain medications indefinitely.
Many patients also fear that weakened Medicare negotiation power will leave them shouldering higher drug costs, especially for expensive treatments like cancer and rare disease therapies.
One multiple sclerosis patient wrote on X (formerly Twitter):
"My medication costs $8,000 a month. If I lose coverage, my only choice is to stop treatment."
Image source: appvoices.org
Jackson James, a policy analyst at the German Marshall Fund (GMF), described the bill as:
"A political maneuver for midterm elections—preserving tax cuts, slashing healthcare, boosting defense, and hardening borders—while gambling with $3.3 trillion in new debt over a decade, risking long-term federal insolvency."
Critics highlight that the bill lacks sustainable cost-control measures, with healthcare cuts detached from long-term public health planning.
DW Television noted:
"This isn’t about controlling healthcare spending—it’s about politicians being able to say, 'I shrank big government.'"
Even some Republicans concede the bill sacrifices healthcare equity to fulfill fiscal austerity and tax-cut promises.
Amid mounting criticism, the Trump administration and House Republicans defended the bill:
"This is a long-overdue fiscal correction—curbing welfare abuse and restoring sanity to America’s healthcare system."
They argue:
However, critics warn that this "market-first" approach overlooks healthcare’s unique role as a public good.
Beyond the grand narratives in policy documents, voices from the medical frontline carry more emotional weight and practical urgency. Within 48 hours of the "Big Beautiful Bill" passing, emergency physicians, community clinic directors, and nonprofit healthcare administrators across America spoke out, revealing the profound disruptions this legislation would trigger within the healthcare system.
On July 4, 2025, in an exclusive interview with DW, Texas emergency physician Dr. Owais Durrani voiced stark warnings:
"About 60% of patients at my hospital rely on Medicaid. Cutting this coverage will directly cause treatment delays until conditions become critical. We won't see 'patients'—we'll see 'emergency cases.'"
Durrani estimates that under the new bill, Texas' uninsured rate would jump from 13% to 20%, causing 55,000 additional preventable deaths annually—not due to lack of medical capability, but lack of access.
The deeper crisis lies in systemic resource paralysis. A Missouri community hospital director explained:
"After initial treatment, patients typically transfer to rehab or nursing facilities—but these Medicaid-dependent institutions may close. Patients can't be discharged, new patients can't be admitted. This two-way congestion will create flood-like paralysis, especially during flu seasons or COVID surges."
As one ER nurse supervisor put it:We don't fear patient volume—we fear having no capacity to care for them.
Kaiser Family Foundation estimates 25% of U.S. nursing facilities risk closure from Medicaid cuts—the primary payer for 60% of long-term residents. This triggers a triple crisis:
One nursing home director asked bitterly:The bill promotes 'self-reliance'—but who cares for an 84-year-old with Alzheimer's when nursing homes disappear?
These safety-net providers for uninsured, low-income, and immigrant populations face funding collapse. Each clinic closure means:
The resulting primary care vacuum will overload hospitals, creating a vicious cycle of concentrated demand.
Hospitals must offset losses from uninsured patients by negotiating higher reimbursement rates with commercial insurers—who will then:
Even middle-class Americans insulated from Medicaid cuts will ultimately pay the price.
Many clinicians shared this anguish: they'll treat anyone who walks in, but refuse to becomestopgaps for policy failures.Chronic understaffing and moral injury from preventable suffering have pushed many to the edge.
"We're not infinite resources. Don't trade budget lines for our conscience."
—San Jose physician
In this upheaval, healthcare institutions are both the first to detect system cracks and the last line of defense patching them—with human lives hanging in the balance.
The "Big Beautiful Bill" represents not just a pivotal moment in U.S. domestic policy but also serves as a magnifying glass and cautionary tale for global healthcare policymaking. For Chinese pharmaceutical professionals, this deep restructuring of America's healthcare system offers three key insights worth pondering:
The U.S. reform attempts to strike a balance between "reducing overall spending" and "maintaining innovation momentum" through Medicaid cuts and exempting certain drugs from price negotiations—a approach bearing similarities to China's centralized procurement and醫保談判 policies.
Yet critical differences emerge:
This reminds Chinese policymakers that excessive price suppression may backfire, potentially:
Policy recommendations for China:
While America's orphan drug exemptions benefit manufacturers, they've also led to unsustainable pricing and patient affordability crises—primarily because exemptions are granted based solely on indication rarity rather than actual cost structures or market dynamics.
China could implement a smarter "dynamic assessment" system:
This approach would ensure rare disease access while preventing policy exploitation.
The chaotic, politicized process behind the "Big Beautiful Bill"—with its repeated revisions and partisan bargaining—has created damaging uncertainty for U.S. industry stakeholders.
China's comparative advantages:
Areas for further improvement:
America's healthcare "storm" isn't isolated—it reflects global struggles with aging populations, technological disruption, and system sustainability. As China's pharmaceutical industry rises, similar challenges await.
Rather than waiting for the winds of change, observe their direction. By learning from others' reforms—both successes and failures—China can better navigate its own path with rhythm and resilience.
The intense debate surrounding the "Big Beautiful Bill"—with its mix of anticipation, concern, and outrage—stems from its fundamental redesign of America's healthcare system. By altering coverage thresholds, disrupting drug pricing mechanisms, and rebalancing power between innovators and payers, it exposes a core dilemma:
In an era of constrained public budgets, aging populations, and rapid technological change, how should nations balance equity, efficiency, and sustainability?
Superficially, the bill favors drugmakers by:
Yet beneath this lies systemic challenges:
Innovators now face existential questions:
A new era of "survival vs. expansion" and "capital vs. value" has begun.
This bill reflects America's fiscal anxieties—a forced choice amid tax cuts, deficits, and demographic pressures. But its collateral damage is profound:
"This isn't a 'beautiful' bill—it's a political IOU paid by future generations."
—Policy Analyst
A warning to global reformers: budget lines must never eclipse lifelines.
When healthcare transforms from universal right to conditional privilege, everyone becomes vulnerable:
The bill reminds us: Healthcare isn't just between doctors and patients—it's about all of us.
The "Big Beautiful Bill" represents:
History will judge whether it becomes:
Beyond judgment lies observation—seeing how policy shifts impact lives, how industry transformations reshape futures. This awareness carries responsibility: to listen, document, and engage as witnesses and participants in healthcare's defining evolution.
 |
 |
 |
